A wearable electrochemical aptamer‑based patch demonstrated continuous, real‑time drug concentration measurements in healthy human participants in a pilot clinical trial, with findings reported in Nature Biotechnology. The device samples dermal interstitial fluid and tracks pharmacokinetics without invasive blood draws, offering a pathway for therapeutic drug monitoring in narrow‑therapeutic‑index medicines. The Nature Biotechnology paper describes the patch’s analytic performance, user tolerability and potential clinical applications — from anticoagulant dosing to oncology agents where plasma level monitoring informs safety and efficacy. The study included an early human feasibility cohort and preclinical validation. If validated in disease populations, the technology could shift inpatient and outpatient drug monitoring paradigms, enabling adaptive dosing, reducing adverse events, and supporting decentralized clinical trials that require longitudinal pharmacokinetic readouts.